Detail akcie Royal Pharm Rg -A online

Business Summary: Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Royalty Pharma plc revenues increased 5% to $2.38B. Net income decreased 10% to $770.9M. Revenues reflect Financial Royalty Assets increase of 5% to $2.26B, Royalty Income Other increase of 3% to $117M. Dividend per share increased from $0.84 to $0.88. Basic Earnings per Share excluding Extraordinary Items decreased from $1.92 to $1.79.